BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38736486)

  • 1. Molecular and immune characterization of Chinese early-stage non-squamous non-small cell lung cancer: a multi-omics cohort study.
    Peng H; Wu X; Cui X; Liu S; Liang Y; Cai X; Shi M; Zhong R; Li C; Liu J; Wu D; Gao Z; Lu X; Luo H; He J; Liang W
    Transl Lung Cancer Res; 2024 Apr; 13(4):763-784. PubMed ID: 38736486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoantigen load as a prognostic and predictive marker for stage II/III non-small cell lung cancer in Chinese patients.
    Gong L; He R; Xu Y; Luo T; Jin K; Yuan W; Zheng Z; Liu L; Liang Z; Li A; Zheng Z; Li H
    Thorac Cancer; 2021 Aug; 12(15):2170-2181. PubMed ID: 34128337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer.
    Wang L; Diao M; Zhang Z; Jiang M; Chen S; Zhao D; Liu Z; Zhou C
    Lung Cancer; 2024 Jan; 187():107439. PubMed ID: 38113653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
    Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
    BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An
    Lin J; Liu J; Hao SG; Lan B; Zheng XB; Xiong JN; Zhang YQ; Gao X; Chen CB; Chen L; Huang YF; Luo H; Yi YT; Yi X; Lu JP; Zheng XW; Chen G; Wang XF; Chen Y
    Front Immunol; 2022; 13():1022598. PubMed ID: 36505399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC.
    He Y; Chen L; Zhao L; Dang S; Liu G; Sasada S; Ma PC; van Zandwijk N; Rosell R; Popper HH; Wang H; Jiang M; Guo H; Liu X; Chen S; Zhang X; Xu M; Zhu B; Liu M; Zhou C
    Theranostics; 2021; 11(14):7092-7109. PubMed ID: 34093873
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
    Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
    BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
    Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
    JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC of Never Smokers.
    Ruel LJ; Li Z; Gaudreault N; Henry C; Saavedra Armero V; Boudreau DK; Zhang T; Landi MT; Labbé C; Couture C; Desmeules P; Joubert P; Bossé Y
    Cancer Epidemiol Biomarkers Prev; 2022 Dec; 31(12):2219-2227. PubMed ID: 36126278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of T cell receptor repertoire in patients with
    Wang Y; Peng L; Zhao M; Xiong Y; Xue J; Li B; Huang Z; Liu X; Yang X; Song Y; Bing Z; Guo C; Tian Z; Gao C; Cao L; Cao Z; Li J; Jiang X; Si X; Zhang L; Li X; Zheng Z; Song M; Chen R; Lim WT; Pavan A; Romero A; Liang N; Yang H; Li S
    Transl Lung Cancer Res; 2022 Sep; 11(9):1936-1950. PubMed ID: 36248331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated investigation of the prognostic role of HLA LOH in advanced lung cancer patients with immunotherapy.
    Zhang X; Tang H; Luo H; Lu H; Pan C; Yu H; Zhang L; Guan Y; Yu L; Chu H; Chen J; Wang J
    Front Genet; 2022; 13():1066636. PubMed ID: 36531232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer.
    Choi SJ; Lee JB; Kim JH; Hong MH; Cho BC; Lim SM
    Ther Adv Med Oncol; 2024; 16():17588359241240657. PubMed ID: 38523846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.
    Reuben A; Gittelman R; Gao J; Zhang J; Yusko EC; Wu CJ; Emerson R; Zhang J; Tipton C; Li J; Quek K; Gopalakrishnan V; Chen R; Vence LM; Cascone T; Vignali M; Fujimoto J; Rodriguez-Canales J; Parra ER; Little LD; Gumbs C; Forget MA; Federico L; Haymaker C; Behrens C; Benzeno S; Bernatchez C; Sepesi B; Gibbons DL; Wargo JA; William WN; Swisher S; Heymach JV; Robins H; Lee JJ; Sharma P; Allison JP; Futreal PA; Wistuba II; Zhang J
    Cancer Discov; 2017 Oct; 7(10):1088-1097. PubMed ID: 28733428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophages-based immune-related risk score model for relapse prediction in stage I-III non-small cell lung cancer assessed by multiplex immunofluorescence.
    Wu XR; Peng HX; He M; Zhong R; Liu J; Wen YK; Li CC; Li JF; Xiong S; Yu T; Zheng HB; Chen YH; He JX; Liang WH; Cai XY
    Transl Lung Cancer Res; 2022 Apr; 11(4):523-542. PubMed ID: 35529784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational status of main driver genes influences the prognosis of stage I-III lung adenocarcinoma patients underwent radical surgery.
    Liao H; Luo X; Liang Y; Wan R; Xu M
    Transl Cancer Res; 2021 Jul; 10(7):3286-3298. PubMed ID: 35116635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer.
    Zhou H; Hu Y; Luo R; Zhao Y; Pan H; Ji L; Zhou T; Zhang L; Long H; Fu J; Wen Z; Wang S; Wang X; Lin P; Yang H; Wang J; Song M; Yi X; Yang L; Xia X; Guan Y; Fang W; Yang Y; Hong S; Huang Y; Li P; Zhang Y; Zhou N
    Nat Commun; 2021 Sep; 12(1):5431. PubMed ID: 34521849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lineage tracing for multiple lung cancer by spatiotemporal heterogeneity using a multi-omics analysis method integrating genomic, transcriptomic, and immune-related features.
    Song Y; Zhou J; Zhao X; Zhang Y; Xu X; Zhang D; Pang J; Bao H; Ji Y; Zhan M; Wang Y; Ou Q; Hu J
    Front Oncol; 2023; 13():1237308. PubMed ID: 37799479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.